 |
인쇄하기
취소
|
Keunwha Pharm faces government review for merger conditions
The M&A agreement executed between Sanofi-Synthelabo and Keunwha Pharm on July 29 this year may be nullified due to the transaction method.
In its reply to a question raised by Keunwha Pharm, the National Tax Service (NTS) said on September 6 that the pharmaceutical business transfer agreement between Sanofi-Synthelabo and Keunwha Pharm is not classified into a comprehensive business transf...
In its reply to a question raised by Keunwha Pharm, the National Tax Service (NTS) said on September 6 that the pharmaceutical business transfer agreement between Sanofi-Synthelabo and Keunwha Pharm is not classified into a comprehensive business transf...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.